Assembly Biosciences, Inc.
ASMB
$9.08
$0.627.33%
| Weiss Ratings | ASMB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | ASMB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ASMB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.80 | |||
| Price History | ASMB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -4.12% | |||
| 30-Day Total Return | -29.50% | |||
| 60-Day Total Return | -37.38% | |||
| 90-Day Total Return | -46.71% | |||
| Year to Date Total Return | -47.06% | |||
| 1-Year Total Return | -39.71% | |||
| 2-Year Total Return | -10.98% | |||
| 3-Year Total Return | -65.29% | |||
| 5-Year Total Return | -95.17% | |||
| 52-Week High % Change | -57.55% | |||
| 52-Week Low % Change | 9.16% | |||
| Price | ASMB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $19.93 | |||
| 52-Week Low Price | $7.75 | |||
| 52-Week Low Price (Date) | Apr 07, 2025 | |||
| 52-Week High Price (Date) | Sep 23, 2024 | |||
| Valuation | ASMB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 63.48M | |||
| Enterprise Value | -45.51M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -6.73 | |||
| Earnings Per Share Growth | -50.86% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 1.94 | |||
| Price/Book (Q) | 1.89 | |||
| Enterprise Value/Revenue (TTM) | -1.60 | |||
| Price | $9.08 | |||
| Enterprise Value/EBITDA (TTM) | 1.00 | |||
| Enterprise Value/EBIT | 1.00 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | ASMB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 6.54M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ASMB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 833 509 4583 | |||
| Address | Two Tower Place South San Francisco, CA 94080 | |||
| Website | www.assemblybio.com | |||
| Country | United States | |||
| Year Founded | 2005 | |||
| Profitability | ASMB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -159.25% | |||
| Profit Margin | -140.87% | |||
| Management Effectiveness | ASMB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -22.18% | |||
| Return on Equity | -- | |||
| Income Statement | ASMB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 28.52M | |||
| Total Revenue (TTM) | 28.52M | |||
| Revenue Per Share | $4.36 | |||
| Gross Profit (TTM) | -27.41M | |||
| EBITDA (TTM) | -45.29M | |||
| EBIT (TTM) | -45.42M | |||
| Net Income (TTM) | -40.18M | |||
| Net Income Avl. to Common (TTM) | -40.18M | |||
| Total Revenue Growth (Q YOY) | 2.71% | |||
| Earnings Growth (Q YOY) | 5.72% | |||
| EPS Diluted (TTM) | -6.73 | |||
| EPS Diluted Growth (Q YOY) | 23.22% | |||
| Balance Sheet | ASMB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 112.08M | |||
| Cash Per Share (Q) | $17.15 | |||
| Total Current Assets (Q) | 115.50M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 33.36M | |||
| Current Ratio (Q) | 2.416 | |||
| Book Value Per Share (Q) | $4.47 | |||
| Total Assets (Q) | 119.17M | |||
| Total Current Liabilities (Q) | 47.80M | |||
| Total Debt (Q) | 3.09M | |||
| Total Liabilities (Q) | 85.81M | |||
| Total Common Equity (Q) | 33.36M | |||
| Cash Flow | ASMB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 40.17M | |||
| Cash from Financing (TTM) | 29.45M | |||
| Net Change in Cash (TTM) | 18.50M | |||
| Levered Free Cash Flow (TTM) | -15.71M | |||
| Cash from Operations (TTM) | -51.12M | |||
